Literature DB >> 26730153

High antibiotic resistance rate: A difficult issue for Helicobacter pylori eradication treatment.

Mei Zhang1.   

Abstract

Helicobacter pylori (H. pylori) infection is associated with a variety of upper gastrointestinal diseases, including gastric cancer. With the wide application of antibiotics in H. pylori eradication treatment, drug-resistant strains of H. pylori are increasing. H. pylori eradication treatment failure affects the outcome of a variety of diseases of the upper gastrointestinal tract. Therefore, antibiotic resistance that affects H. pylori eradication treatment is a challenging situation for clinicians. The ideal H. pylori eradication therapy should be safe, effective, simple, and economical. The eradication rate of triple antibiotic therapy is currently less than 80% in most parts of the world. Antibiotic resistance is the main reason for treatment failure, therefore the standard triple regimen is no longer suitable as a first-line treatment in most regions. H. pylori eradication treatment may fail for a number of reasons, including H. pylori strain factors, host factors, environmental factors, and inappropriate treatment.

Entities:  

Keywords:  Eradication treatment; Gastrointestinal disease; Helicobacter pylori; Resistance; Triple antibiotic therapy

Mesh:

Substances:

Year:  2015        PMID: 26730153      PMCID: PMC4690171          DOI: 10.3748/wjg.v21.i48.13432

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  36 in total

Review 1.  H pylori antibiotic resistance: prevalence, importance, and advances in testing.

Authors:  F Mégraud
Journal:  Gut       Date:  2004-09       Impact factor: 23.059

2.  Failure of Helicobacter pylori eradication: is poor compliance the main cause?

Authors:  Joël Wermeille; Michael Cunningham; Jean-Pierre Dederding; Laurent Girard; Rémy Baumann; Georges Zelger; Pierre Buri; Jean-Michel Metry; Radan Sitavanc; Landri Gallaz; Hans Merki; Norman Godin
Journal:  Gastroenterol Clin Biol       Date:  2002-03

3.  Rapid detection of clarithromycin resistance in Helicobacter pylori using a PCR-based denaturing HPLC assay.

Authors:  Patrizia Posteraro; Giovanna Branca; Maurizio Sanguinetti; Stefania Ranno; Giovanni Cammarota; Siavash Rahimi; Mario De Carlo; Brunella Posteraro; Giovanni Fadda
Journal:  J Antimicrob Chemother       Date:  2005-11-11       Impact factor: 5.790

4.  Importance of Helicobacter pylori cagA and vacA status for the efficacy of antibiotic treatment.

Authors:  L J van Doorn; P M Schneeberger; N Nouhan; A P Plaisier; W G Quint; W A de Boer
Journal:  Gut       Date:  2000-03       Impact factor: 23.059

5.  Mutations in 23S rRNA are associated with clarithromycin resistance in Helicobacter pylori.

Authors:  J Versalovic; D Shortridge; K Kibler; M V Griffy; J Beyer; R K Flamm; S K Tanaka; D Y Graham; M F Go
Journal:  Antimicrob Agents Chemother       Date:  1996-02       Impact factor: 5.191

6.  Risk factors for failure of Helicobacter pylori therapy--results of an individual data analysis of 2751 patients.

Authors:  N Broutet; S Tchamgoué; E Pereira; H Lamouliatte; R Salamon; F Mégraud
Journal:  Aliment Pharmacol Ther       Date:  2003-01       Impact factor: 8.171

7.  Helicobacter pylori resistance to antibiotics in Europe and its relationship to antibiotic consumption.

Authors:  Francis Megraud; Samuel Coenen; Ann Versporten; Manfred Kist; Manuel Lopez-Brea; Alexander M Hirschl; Leif P Andersen; Herman Goossens; Youri Glupczynski
Journal:  Gut       Date:  2012-05-12       Impact factor: 23.059

8.  Seroepidemiology of Helicobacter pylori infection in elderly people in the Beijing region, China.

Authors:  Mei Zhang; Ying-Zhi Zhou; Xiao-Ying Li; Zhe Tang; Hong-Ming Zhu; Yan Yang; Jagadish K Chhetri
Journal:  World J Gastroenterol       Date:  2014-04-07       Impact factor: 5.742

9.  Effect of CYP2C19 genetic polymorphisms on the efficacy of proton pump inhibitor-based triple therapy for Helicobacter pylori eradication: a meta-analysis.

Authors:  Fujun Zhao; Jing Wang; Yanmei Yang; Xiaoyong Wang; Ruihua Shi; Zekuan Xu; Zuhu Huang; Guoxin Zhang
Journal:  Helicobacter       Date:  2008-12       Impact factor: 5.753

10.  Ten day sequential versus 10 day modified bismuth quadruple therapy as empirical firstline and secondline treatment for Helicobacter pylori in Chinese patients: an open label, randomised, crossover trial.

Authors:  Kevin S H Liu; Ivan F N Hung; W K Walter Seto; Teresa Tong; Axel S J Hsu; Frank Y F Lam; David Y K But; S Y Wong; Wai K Leung
Journal:  Gut       Date:  2013-12-02       Impact factor: 23.059

View more
  23 in total

1.  Selective killing of Helicobacter pylori with pH-responsive helix-coil conformation transitionable antimicrobial polypeptides.

Authors:  Menghua Xiong; Yan Bao; Xin Xu; Hua Wang; Zhiyuan Han; Zhiyu Wang; Yeqing Liu; Songyin Huang; Ziyuan Song; Jinjing Chen; Richard M Peek; Lichen Yin; Lin-Feng Chen; Jianjun Cheng
Journal:  Proc Natl Acad Sci U S A       Date:  2017-11-13       Impact factor: 11.205

2.  Coating nanoparticles with gastric epithelial cell membrane for targeted antibiotic delivery against Helicobacter pylori infection.

Authors:  Pavimol Angsantikul; Soracha Thamphiwatana; Qiangzhe Zhang; Kevin Spiekermann; Jia Zhuang; Ronnie H Fang; Weiwei Gao; Marygorret Obonyo; Liangfang Zhang
Journal:  Adv Ther (Weinh)       Date:  2018-05-08

Review 3.  Effectiveness and Safety of Rifaximin-Containing Regimens for Helicobacter pylori Eradication: Systematic Review - Are They Potential Eradication Regimens?

Authors:  Yu Wang; Jiong Tang; Su Zhou; Tian-Tian Liang; Fang-Fang Wang; Hong Ning
Journal:  Infect Drug Resist       Date:  2022-07-13       Impact factor: 4.177

4.  A Survey of Helicobacter pylori Antibiotic-Resistant Genotypes and Strain Lineages by Whole-Genome Sequencing in China.

Authors:  Yan Zhou; Zishao Zhong; Shengjuan Hu; Jing Wang; Yanhong Deng; Ximei Li; Xianmei Chen; Xue Li; Yuanyuan Tang; Xiaofei Li; Qian Hao; Jun Liu; Tian Sang; Yang Bo; Feihu Bai
Journal:  Antimicrob Agents Chemother       Date:  2022-06-02       Impact factor: 5.938

5.  Antibiotic resistance of Helicobacter pylori to 16 antibiotics in clinical patients.

Authors:  Yongfu Shao; Rongdan Lu; Yunben Yang; Qiancheng Xu; Bojun Wang; Guoliang Ye
Journal:  J Clin Lab Anal       Date:  2017-10-06       Impact factor: 2.352

6.  The influence of P-glycoprotein expression in the standard treatment of Helicobacter pylori infection in Sprague Dawley rats.

Authors:  Noor Safwah Damanhuri; Endang Kumolosasi; Marhanis Salihah Omar; Amirul Faiz Abd Razak; Ahmad Hasnan Mansor
Journal:  Daru       Date:  2021-01-06       Impact factor: 3.117

7.  Antimicrobial susceptibility and clarithromycin resistance patterns of Helicobacter pylori clinical isolates in Vietnam.

Authors:  Camelia Quek; Son T Pham; Kieu T Tran; Binh T Pham; Loc V Huynh; Ngan B L Luu; Thao K T Le; Kelly Quek; Van H Pham
Journal:  F1000Res       Date:  2016-04-13

8.  The Bifunctional Enzyme SpoT Is Involved in the Clarithromycin Tolerance of Helicobacter pylori by Upregulating the Transporters HP0939, HP1017, HP0497, and HP0471.

Authors:  Xiwen Geng; Wen Li; Zhenghong Chen; Sizhe Gao; Wei Hong; Xiaoran Ge; Guihua Hou; Zhekai Hu; Yabin Zhou; Beini Zeng; Wenjuan Li; Jihui Jia; Yundong Sun
Journal:  Antimicrob Agents Chemother       Date:  2017-04-24       Impact factor: 5.191

9.  A Comparative Study of Efficacy and Safety of Two Eradication Regimens for Helicobacter pylori Infection.

Authors:  Carmen Monica Preda; Doina Proca; Irina Sandra; Larisa Elena Fulger; Boroka Claudia Horeanga; Mircea Manuc; Teodora Manuc; Catalin Andrei Dutei; Mihaela Barbu; Letitia Tugui; Adriana-Corina Andrei; Bogdan Ionut Slavulete; Mircea Diculescu
Journal:  Maedica (Bucur)       Date:  2017-09

10.  Efficacy and safety of Zuojin Pill for chronic gastritis: Protocol for a systematic review of randomized controlled trials.

Authors:  Jianglong Shi; Liyun Liu; Jian Li; Xiaoju Ma; Hairong Qiu; Tao Shen
Journal:  Medicine (Baltimore)       Date:  2020-07-17       Impact factor: 1.817

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.